Summit Therapeutics Inc.

Stocks

SMMT

US86627T1088

Market Closed - Nasdaq 00:00:00 03/10/2026 +04			5-day change	1st Jan Change
16.76 ^USD	+0.39%		+7.34%	-4.20%

09-22	Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026	CI
09-15	Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients	CI

Transcript : Summit Therapeutics Inc. - Special Call

Published on 09/08/2025 at 07:37 pm +04 - Modified on 09/08/2025 at 10:50 pm +04

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Summit

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Summit Therapeutics Inc.

09-22	Akeso, Inc. and Summit Therapeutics Inc. Showcase HARMONi-G11 Phase III Trial Data Featuring Ivonescimab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer At ESMO 2026	CI
09-15	Summit Therapeutics Presents Updated HarmonI Data At WCLC 2026 Demonstrating Consistent Overall Survival Results With Ivonescimab Plus Chemotherapy In Western And Asian Patients	CI
09-14	Summit Therapeutics Shares Rise After Partner Akeso's Ivonescimab Phase 3 Lung Cancer Study in China Shows Survival Benefit	MT
09-09	Summit Therapeutics Shares Rise After Upgrade From Jefferies	MT
09-09	Jefferies Upgrades Summit Therapeutics to Buy From Hold, Adjusts Price Target to $25 From $15	MT
08-26	Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Wednesday Amid Inflation Data Release	MT
08-26	US Equity Futures Mostly Flat Pre-Bell as Traders Weigh Inflation Data, Await Nvidia Results	MT
08-26	Summit Therapeutics Says Partner's Potential Biliary Tract Cancer Treatment Meets Primary, Secondary Endpoints	MT
08-26	Summit Therapeutics Reports Positive Topline Results From Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy In First-Line Advanced Biliary Tract Cancer	CI
08-25	Wall Street Wants Receipts
08-25	Analyst recommendations: AMD, Dynatrace, Elastic, Revolution Medicines…
08-12	Summit Therapeutics Says Its Partner Akeso Gets China Approval for Ivonescimab in Squamous NSCLC	MT
08-12	Leerink Partners Upgrades Summit Therapeutics to Market Perform From Underperform, Adjusts PT to $13 From $12	MT
08-05	Summit Therapeutics Expands Ivonescimab Global Development Program With Phase II/III Harmonigu1 Study In First-Line Bladder Cancer	CI
07-24	Jefferies Cuts Summit Therapeutics Price Target to $15 From $17, Hold Rating Kept	MT